RICHLAND, Wash.--(BUSINESS WIRE)--IsoRay, Inc. (“IsoRay”) (OTCBB:ISRY), a medical technology company focusing on innovative treatment for prostate cancer and other solid cancer tumors through use of its proprietary Cesium-131 brachytherapy seeds, announced that the Securities and Exchange Commission will declare its Registration Statement effective today at 5 p.m. (Eastern Time). Shareholders must still comply with various state securities regulations to complete their sales.
